- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01235507
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
Actemra - Local Bosnian Open, Multicentric, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis After Inadequate Response to DMARDs
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Banja Luka, Bósnia e Herzegovina, 78 000
-
Sarajevo, Bósnia e Herzegovina, 71000
-
Tuzla, Bósnia e Herzegovina, 75000
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Active moderate to severe rheumatoid arthritis (RA)
- On methotrexate treatment (oral or parenteral) for at least 12 weeks, at stable dose of at least 15 mg/week for at least 6 weeks
- Oral corticosteroids must have been at stable dose of </= 10 mg/day prednisone (or equivalent) for at least 25 out of 28 days prior to first dose of study drug
- Body weight </= 150 kg
Exclusion Criteria:
- Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months of study entry
- Rheumatic autoimmune disease other than RA
- Functional class IV according to American College of Rheumatology (ACR) classification
- Prior history of or current inflammatory joint disease other then RA
- Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline
- Treatment with any biologic drug that is used in the treatment or RA
- Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline
- Known active current or history of recurrent infection
- History of or currently active primary or secondary immunodeficiency
- Positive for HIV
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Braço único
|
stable dose as prescribed
8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)
Prazo: Screening Visit, Baseline, Weeks 4, 8, 12, 16, 20 and 24
|
AEs, SAEs and AESI were recorded from the Screening Visit until the final visit at Week 24.
|
Screening Visit, Baseline, Weeks 4, 8, 12, 16, 20 and 24
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean Disease Activity Score Based on 28 Joint Count (DAS28) by Visit
Prazo: Baseline, Weeks 8, 16 and 24
|
DAS28 was calculated using the 28 joints count, the C-reactive protein levels (CRP) and participant's global assessment (PtGA) of disease activity. The following formula was used to determine DAS28. DAS28 (equals) = 0.56 × (square root of) √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100- millimeter [mm] visual analog scale [ VAS]). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. |
Baseline, Weeks 8, 16 and 24
|
Percentage of Participants Achieving Low Disease Activity (LDA) and Clinical Remission (CR) as Assessed Using DAS28
Prazo: Weeks 8, 16 and 24
|
DAS28 was calculated using the 28 joints count, the CRP and PtGA of disease activity. The following formula was used to determine DAS28. DAS28 = 0.56 × √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100-mm VAS). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Participants were considered to have low disease activity when DAS28 was less than or equal to (≤) 3.2 and in clinical remission when DAS28 scores were less than (<) 2.6 |
Weeks 8, 16 and 24
|
Swollen and Tender Joint Counts
Prazo: Baseline, Weeks 8, 16 and 24
|
66 and 68 joints were assessed by the physician for tenderness or swelling respectively.
The joints were counted as tender/not tender (tender=1; not tender=0) and swollen/not swollen (swollen=1; not swollen=0) and scored.
The scores ranged from 0 to 66 for TJC and 0 to 68 for SJC.
A negative change from baseline represents an improvement.
|
Baseline, Weeks 8, 16 and 24
|
Physician's Global Assessment of Disease Activity
Prazo: Baseline, Weeks 8, 16 and 24
|
Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100).
The distance in mm from the left edge of the scale was measured.
Higher scores indicated higher disease activity.
A negative change from baseline represents an improvement.
|
Baseline, Weeks 8, 16 and 24
|
Participant's Global Assessment of Disease Activity
Prazo: Baseline, Weeks 8, 16 and 24
|
Participant's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100).
The distance in mm from the left edge of the scale was measured.
Higher scores indicated higher disease activity.
A negative change from baseline represents an improvement.
|
Baseline, Weeks 8, 16 and 24
|
Participant's Global Assessment of Pain
Prazo: Baseline, Weeks 8, 16 and 24
|
Participant's global assessment of pain was performed using a 100 mm VAS ranging from no pain (0) at the left edge to unbearable pain (100) at the right edge.
The distance in mm from the left edge of the scale was measured.
A negative change from baseline represents an improvement.
|
Baseline, Weeks 8, 16 and 24
|
CRP Levels
Prazo: Baseline, Weeks 8, 16 and 24
|
CRP is a marker of acute phase inflammation and is measured in mg/L.
A negative change from baseline represents an improvement.
|
Baseline, Weeks 8, 16 and 24
|
Erythrocyte Sedimentation Rate (ESR)
Prazo: Baseline, Weeks 8, 16 and 24
|
ESR is a marker of inflammation and is measured in millimeters per hour (mm/hour).
A negative change from baseline represents an improvement.
|
Baseline, Weeks 8, 16 and 24
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do sistema imunológico
- Doenças autoimunes
- Doenças articulares
- Doenças musculoesqueléticas
- Doenças Reumáticas
- Doenças do Tecido Conjuntivo
- Artrite
- Artrite, Reumatóide
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores da Síntese de Ácido Nucleico
- Inibidores Enzimáticos
- Agentes Antirreumáticos
- Antimetabólitos, Antineoplásicos
- Antimetabólitos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Agentes dermatológicos
- Agentes de Controle Reprodutivo
- Agentes abortivos, não esteróides
- Agentes abortivos
- Antagonistas do ácido fólico
- Metotrexato
Outros números de identificação do estudo
- ML25303
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .